Central pathology review in clinical trials for patients with malignant glioma. A report of radiation therapy oncology group 83‐02

Cancer

Volumn 76, Issue 2, 1995, Pages 307-313

  Scott, Charles B ^a   Nelson, James S ^b   Farnan, Nancy C ^a   Curran, Walter J ^c   Murray, Kevin J ^d   Fischbach, A Jennifer ^e   Gaspar, Laurie E ^f   Nelson, Diana F ^g  

^a Radiation Thrapy Oncology Group ^*  (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e LDS HOSPITAL   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

anaplastic astrocytoma; clinical trials; glioblastoma multiforme; glioma

Indexed keywords

ARTICLE; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC VALUE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

ADULT; AGED; ASTROCYTOMA; CARMUSTINE; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; GLIOBLASTOMA; HUMAN; MIDDLE AGE; PROGNOSIS; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS;

EID: 0029042988     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950715)76:2<307::AID-CNCR2820760222>3.0.CO;2-L     Document Type: Article

References (19)

1. Necrosis as a prognostic criterion in malignant supratentorial astrocytic gliomas
2. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications
3. Survival and prognosis of patients with astrocytomas with atypical or anaplastic features
4. Hyperfractionated radiation therapy and bischlorethyl nitrosourea in the treatment of malignant glioma—possible advantage observed at 72.0 Gy in 1.2 Gy b.i.d. fractions: report of the Radiation Therapy Oncology Group Protocol 8302
5. A randomized trial of accelerated hyperfractionated radiation therapy and bis‐chlorethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83‐02
6. The management of malignant gliomas with radiation therapy: therapeutic results and research strategies
7. Initial analysis of NCOG 6G82‐1: bromodeoxyuridine (BUdR) during irradiation followed by CCNU, procarbazine, and vincristine (PCV) chemotherapy for malignant gliomas [abstract]
8. External irradiation followed by an interstitial high activity iodine‐125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G‐82‐2
9. Asymptotically efficient rank invariant test procedures
10. Censored data and the bootstrap
11. Nonparametric estimation from incomplete observations
12. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials
13. Contemporary approaches to the treatment of malignant gliomas with radiation therapy
14. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas
15. A Monte Carlo study of the power of some two‐sample tests